Pluristem Therapeutics Inc is a biotechnology business based in the US. Pluristem Therapeutics shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem Therapeutics employs 146 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Pluristem Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PSTI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Pluristem Therapeutics stock price (NASDAQ: PSTI)Use our graph to track the performance of PSTI stocks over time.
Pluristem Therapeutics shares at a glance
|Latest market close||$3.68|
|52-week range||$3.34 - $12.15|
|50-day moving average||$3.92|
|200-day moving average||$5.14|
|Wall St. target price||$9.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.86|
Buy Pluristem Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Pluristem Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pluristem Therapeutics price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||-10.46%|
|3 months (2021-04-28)||-18.58%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Pluristem Therapeutics financials
|Gross profit TTM||$23,000|
|Return on assets TTM||-54.49%|
|Return on equity TTM||-105.54%|
|Market capitalisation||$108.9 million|
TTM: trailing 12 months
Shorting Pluristem Therapeutics shares
There are currently 696,959 Pluristem Therapeutics shares held short by investors – that's known as Pluristem Therapeutics's "short interest". This figure is 127.7% up from 306,052 last month.
There are a few different ways that this level of interest in shorting Pluristem Therapeutics shares can be evaluated.
Pluristem Therapeutics's "short interest ratio" (SIR)
Pluristem Therapeutics's "short interest ratio" (SIR) is the quantity of Pluristem Therapeutics shares currently shorted divided by the average quantity of Pluristem Therapeutics shares traded daily (recently around 458525.65789474). Pluristem Therapeutics's SIR currently stands at 1.52. In other words for every 100,000 Pluristem Therapeutics shares traded daily on the market, roughly 1520 shares are currently held short.
However Pluristem Therapeutics's short interest can also be evaluated against the total number of Pluristem Therapeutics shares, or, against the total number of tradable Pluristem Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pluristem Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pluristem Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0254% of the tradable shares (for every 100,000 tradable Pluristem Therapeutics shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pluristem Therapeutics.
Find out more about how you can short Pluristem Therapeutics stock.
Pluristem Therapeutics share dividends
We're not expecting Pluristem Therapeutics to pay a dividend over the next 12 months.
Have Pluristem Therapeutics's shares ever split?
Pluristem Therapeutics's shares were split on a 1:10 basis on 24 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem Therapeutics shares which in turn could have impacted Pluristem Therapeutics's share price.
Pluristem Therapeutics share price volatility
Over the last 12 months, Pluristem Therapeutics's shares have ranged in value from as little as $3.34 up to $12.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem Therapeutics's is 2.339. This would suggest that Pluristem Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Pluristem Therapeutics overview
Pluristem Therapeutics Inc. , together with its subsidiary, Pluristem Ltd. , operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells.
Stocks similar to Pluristem Therapeutics
Pluristem Therapeutics in the news
Stocks That Hit 52-Week Lows On Tuesday
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Frequently asked questionsWhat percentage of Pluristem Therapeutics is owned by insiders or institutions?
Currently 13.924% of Pluristem Therapeutics shares are held by insiders and 20.042% by institutions. How many people work for Pluristem Therapeutics?
Latest data suggests 146 work at Pluristem Therapeutics. When does the fiscal year end for Pluristem Therapeutics?
Pluristem Therapeutics's fiscal year ends in June. Where is Pluristem Therapeutics based?
Pluristem Therapeutics's address is: Building No. 5, Haifa, Israel, 31905 What is Pluristem Therapeutics's ISIN number?
Pluristem Therapeutics's international securities identification number is: US72940R3003 What is Pluristem Therapeutics's CUSIP number?
Pluristem Therapeutics's Committee on Uniform Securities Identification Procedures number is: 72940P106
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert